Latest news with #XLO
Yahoo
5 days ago
- Business
- Yahoo
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
Xilio Therapeutics (NASDAQ:XLO) Second Quarter 2025 Results Key Financial Results Revenue: US$8.08m (up 243% from 2Q 2024). Net loss: US$15.8m (loss widened by 14% from 2Q 2024). US$0.16 loss per share. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Xilio Therapeutics Earnings Insights Looking ahead, revenue is expected to decline by 4.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. Performance of the American Biotechs industry. The company's shares are up 6.9% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 5 warning signs for Xilio Therapeutics (of which 1 is a bit concerning!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
02-06-2025
- Business
- Business Insider
Xilio Therapeutics announces updated Phase 2 data for vilastobart
Xilio Therapeutics (XLO) announced updated data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic MSS CRC. The data will be presented in a poster session at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. Results include: 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases; Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms; MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C remains on treatment after more than 14 months; combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events Confident Investing Starts Here:
